Northern Trust’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.8M | Sell |
724,259
-9,171
| -1% | -$178K | ﹤0.01% | 1821 |
|
|
2025
Q4 | $15.8M | Buy |
733,430
+94,650
| +15% | +$1.99M | ﹤0.01% | 1822 |
|
|
2025
Q3 | $12.3M | Sell |
638,780
-120,773
| -16% | -$2.15M | ﹤0.01% | 1992 |
|
|
2025
Q2 | $13M | Sell |
759,553
-10,264
| -1% | -$438K | ﹤0.01% | 1916 |
|
|
2025
Q1 | $49.1M | Sell |
769,817
-33,694
| -4% | -$3.55M | 0.01% | 1093 |
|
|
2024
Q4 | $97.7M | Buy |
803,511
+147,874
| +23% | +$18.1M | 0.01% | 727 |
|
|
2024
Q3 | $81.9M | Sell |
655,637
-12,441
| -2% | -$1.72M | 0.01% | 751 |
|
|
2024
Q2 | $106M | Buy |
668,078
+237,255
| +55% | +$30.5M | 0.02% | 614 |
|
|
2024
Q1 | $55.8M | Sell |
430,823
-6,743
| -2% | -$826K | 0.01% | 911 |
|
|
2023
Q4 | $42.2M | Buy |
437,566
+12,143
| +3% | +$1.16M | 0.01% | 1118 |
|
|
2023
Q3 | $51.6M | Buy |
425,423
+14,868
| +4% | +$1.68M | 0.01% | 912 |
|
|
2023
Q2 | $47M | Buy |
410,555
+10,136
| +3% | +$1.31M | 0.01% | 1015 |
|
|
2023
Q1 | $55.2M | Buy |
400,419
+8,793
| +2% | +$1.14M | 0.01% | 890 |
|
|
2022
Q4 | $50.7M | Buy |
391,626
+6,073
| +2% | +$704K | 0.01% | 918 |
|
|
2022
Q3 | $42.6M | Buy |
385,553
+2,526
| +0.7% | +$255K | 0.01% | 949 |
|
|
2022
Q2 | $28.7M | Sell |
383,027
-17,599
| -4% | -$1.29M | 0.01% | 1287 |
|
|
2022
Q1 | $31.3M | Sell |
400,626
-5,545
| -1% | -$425K | 0.01% | 1363 |
|
|
2021
Q4 | $36.6M | Buy |
406,171
+13,744
| +4% | +$1.17M | 0.01% | 1333 |
|
|
2021
Q3 | $36.3M | Buy |
392,427
+4,217
| +1% | +$325K | 0.01% | 1340 |
|
|
2021
Q2 | $30.2M | Sell |
388,210
-94,592
| -20% | -$7.17M | 0.01% | 1589 |
|
|
2021
Q1 | $36M | Sell |
482,802
-7,995
| -2% | -$738K | 0.01% | 1391 |
|
|
2020
Q4 | $83.7M | Buy |
490,797
+2,672
| +0.5% | +$396K | 0.02% | 722 |
|
|
2020
Q3 | $68.5M | Buy |
488,125
+10,982
| +2% | +$1.67M | 0.02% | 729 |
|
|
2020
Q2 | $76.5M | Buy |
477,143
+16,316
| +4% | +$2.22M | 0.02% | 631 |
|
|
2020
Q1 | $45.1M | Buy |
460,827
+22,486
| +5% | +$2.57M | 0.01% | 833 |
|
|
2019
Q4 | $56.6M | Buy |
438,341
+2,606
| +0.6% | +$263K | 0.01% | 931 |
|
|
2019
Q3 | $32.8M | Buy |
435,735
+100,157
| +30% | +$11.8M | 0.01% | 1292 |
|
|
2019
Q2 | $51M | Buy |
335,578
+22,903
| +7% | +$2.78M | 0.01% | 982 |
|
|
2019
Q1 | $37.3M | Sell |
312,675
-5,612
| -2% | -$721K | 0.01% | 1205 |
|
|
2018
Q4 | $34.7M | Buy |
318,287
+19,473
| +7% | +$2.44M | 0.01% | 1130 |
|
|
2018
Q3 | $48.3M | Buy |
298,814
+627
| +0.2% | +$85.7K | 0.01% | 1057 |
|
|
2018
Q2 | $39.4M | Sell |
298,187
-415,572
| -58% | -$39.2M | 0.01% | 1223 |
|
|
2018
Q1 | $52.9M | Sell |
713,759
-413
| -0.1% | -$27.5K | 0.01% | 949 |
|
|
2017
Q4 | $39.7M | Buy |
714,172
+3,530
| +0.5% | +$187K | 0.01% | 1169 |
|
|
2017
Q3 | $32.2M | Buy |
710,642
+81,138
| +13% | +$3.24M | 0.01% | 1326 |
|
|
2017
Q2 | $21.2M | Buy |
629,504
+20,680
| +3% | +$673K | 0.01% | 1626 |
|
|
2017
Q1 | $18M | Buy |
608,824
+28,301
| +5% | +$876K | 0.01% | 1707 |
|
|
2016
Q4 | $15.9M | Buy |
580,523
+72,956
| +14% | +$2.93M | ﹤0.01% | 1765 |
|
|
2016
Q3 | $31.2M | Buy |
507,567
+2,930
| +0.6% | +$88.6K | 0.01% | 1217 |
|
|
2016
Q2 | $9.62M | Sell |
504,637
-26,760
| -5% | -$496K | ﹤0.01% | 2051 |
|
|
2016
Q1 | $10.4M | Buy |
531,397
+15,330
| +3% | +$268K | ﹤0.01% | 1954 |
|
|
2015
Q4 | $19.9M | Buy |
516,067
+46,953
| +10% | +$1.52M | 0.01% | 1515 |
|
|
2015
Q3 | $15.1M | Buy |
469,114
+11,048
| +2% | +$375K | 0.01% | 1699 |
|
|
2015
Q2 | $13.9M | Buy |
458,066
+7,161
| +2% | +$146K | ﹤0.01% | 1845 |
|
|
2015
Q1 | $5.99M | Buy |
450,905
+6,352
| +1% | +$84.7K | ﹤0.01% | 2397 |
|
|
2014
Q4 | $6.43M | Sell |
444,553
-14,036
| -3% | -$238K | ﹤0.01% | 2336 |
|
|
2014
Q3 | $9.68M | Sell |
458,589
-9,175
| -2% | -$207K | ﹤0.01% | 2066 |
|
|
2014
Q2 | $13.9M | Sell |
467,764
-21,803
| -4% | -$689K | ﹤0.01% | 1802 |
|
|
2014
Q1 | $11.8M | Sell |
489,567
-46,208
| -9% | -$1.18M | ﹤0.01% | 1983 |
|
|
2013
Q4 | $10.9M | Buy |
535,775
+56,969
| +12% | +$1.69M | ﹤0.01% | 2032 |
|
|
2013
Q3 | $22.6M | Buy |
478,806
+271,471
| +131% | +$10.5M | 0.01% | 1363 |
|
|
2013
Q2 | $7.89M | Buy |
+207,335
| New | +$7.41M | ﹤0.01% | 2099 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
Northern Trust's SRPT Position: Q1 2026 in Review
Northern Trust reduced its Sarepta Therapeutics (SRPT) stake by 1.3% in Q1 2026, selling an estimated $178K and leaving 724,259 shares worth $15.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1821.
Northern Trust first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $106M in Q2 2024. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Northern Trust held 724,259 shares of Sarepta Therapeutics worth $15.8M as of Q1 2026.
- Northern Trust sold 9,171 Sarepta Therapeutics shares in Q1 2026, an estimated $178K.
- Sarepta Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1821 holding.
- Northern Trust first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Northern Trust's Sarepta Therapeutics position peaked at $106M in Q2 2024.
- 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.